ValuEngine upgraded shares of Trimel Pharmaceuticals (OTCMKTS:TRLPF) from a sell rating to a hold rating in a research note published on Monday morning.

Trimel Pharmaceuticals (TRLPF) opened at $0.29 on Monday. Trimel Pharmaceuticals has a 1-year low of $0.08 and a 1-year high of $0.40. The company has a quick ratio of 0.94, a current ratio of 1.81 and a debt-to-equity ratio of 0.20.

TRADEMARK VIOLATION NOTICE: “Trimel Pharmaceuticals (TRLPF) Rating Increased to Hold at ValuEngine” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at

Trimel Pharmaceuticals Company Profile

Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Trimel Pharmaceuticals Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trimel Pharmaceuticals Corp. and related companies with's FREE daily email newsletter.